Do CYP2D6 variations matter for women on tamoxifen? Variations may affect how women metabolize tamoxifen, but do they make a difference in breast cancer recurrence or prevention? Recent studies suggest maybe not. Today we'll share the latest news and research on how CYP2D6 variations affect women on tamoxifen.
Background from the Dr. Susan Love Research Foundation
An overview from the Dr. Susan Love Research Foundation provides a nice background to the issue. Essentially, a gene called cytochrome P450 2D6 generates an enzyme called CYP2D6. Variations in the gene affect the enzyme production and affect how well a woman metabolizes, or processes tamoxifen. Some women process it better than others.
A 2007 study suggested that women with a certain variation were almost twice as likely to have their cancer recur. Subsequently, some specialists started recommending CYP2D6 testing before starting tamoxifen.
Later studies, however, found that variations in CYP2D6 made no difference in breast cancer recurrence. Dr. Love's website notes that more studies are needed to resolve the inconsistency in the research.
The Latest Research
Dr. Love's website was updated in January 2011. What has happened since then? Studies on CYP2D6 and tamoxifen continue to trickle in. Today we'll share the latest research. Links to all of the studies discussed below may be found on the CYP2D6 testing page of our website.
CYP2D6 variations when tamoxifen is prescribed for prevention
Tamoxifen is sometimes prescribed to prevent breast cancer in women at high-risk. An August 31 study in Clinical Cancer Research found that CYP2D6 variations made no difference in whether or not tamoxifen or Evista (raloxifene) were effective when taken to prevent breast cancer.
CYP2D6 variations when tamoxifen is prescribed to prevent recurrence.
Tamoxifen is also prescribed to prevent recurrence in women treated for breast cancer. Since January 2011, three studies have suggested that CYP2D6 variations make no difference in breast cancer recurrence rates for women on tamoxifen.
A January 15 study in the Journal of the National Cancer Institute from Denmark found, "The association between CYP2D6 inhibition and recurrence in tamoxifen-treated patients is likely null or small."
In a March 25 study in Breast Cancer Research and Treatment from Korea, CYP2D6 variations were not associated with clinical outcomes, such as recurrence, in early-stage breast cancer patients treated with tamoxifen.
Most recently, an August 5 MD Anderson study in Cancer found "no significant effect of CYP2D6 genotype on risk of recurrence in breast cancer patients who received adjuvant tamoxifen therapy."
Current Recommendations
Due to the current state of research, the 2011 National Comprehensive Cancer Network (NCCN) Guidelines do recommend CY2D6 testing for evaluating treatment with tamoxifen. (See March 21 OncLive.com article.)
In Europe, according to the 2011 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, "The Panel was almost unanimous in rejecting CYP2D6 testing to dictate choice of endocrine therapy type." In the UK, a cost/benefit analysis in the September issue of Health Technology Assessment concluded that CYP2D6 testing could not be recommended at this time due to the rapidly evolving research and limited and conflicting data.
At LATESTBreastCancer.com, we'll continue to follow the research in CYP2D6 testing and tamoxifen. We'll add any developments to our website and database and highlight them in this blog. Please stay tuned.
Showing posts with label tamoxifen. Show all posts
Showing posts with label tamoxifen. Show all posts
Wednesday, September 21, 2011
Monday, September 19, 2011
Breast Cancer News Weekly Wrap-Up (Sept. 12 to 18)
Today we'll wrap-up last week's breast cancer news. Topics include hot flashes, fatigue, mammography and environmental BPAs. Links to the news and research below may be found on the treatment pages of the LATESTBreastCancer.com website.
Effexor and Catapres effective for hot flashes
Some breast cancer treatments may induce menopause and cause unpleasant side effects such as hot flashes. A September 12 study in the Journal of Clinical Oncology compared Effexor (venlafaxine) to Catapres (clonidine) to a placebo for the treatment of hot flashes in breast cancer patients.
Both Effexor and Catapres were found to be effective in the management of hot flashes. Effexor resulted in a more immediate reduction in hot flashes, but at week 12, hot flashes were lower in the Catapres group. Reports of nausea, constipation and appetite loss were higher in the Effexor group.
A September 12 Family Practice News report on the study included a commentary which noted that the small size of the study was its "main weakness." In the end, only 35 patients took Effexor, 28 Catapres and 17 the placebo. A larger study would be needed to "reliably identify suspected differences between the study arms." Also, the study authors noted that the duration of the study may have been too short to adequately assess side effects.
Nonetheless, in the Family Practice News story, study authors said the "more rapid reduction in hot flashes suggests that venlafaxine is to be preferred over clonidine." They advised 37.5 mg daily in the first week, increasing to 75 mg "if greater efficacy is desired."
Fatigue after treatment associated with pain and depression
Last week EurekAlert! and the UPI covered a study from Spain on fatigue in breast cancer survivors. The study found that patients most affected by fatigue also suffered "episodes of depression, body image deterioration, neck and shoulder pain, and limited arm movement, possibly due to the surgical intervention," such as breast conserving surgery (lumpectomy) and mastectomy.
The lead author noted that these findings should "motivate" patient support programs to provide resources to improve psychological states and pain to improve fatigue.
Higher mammography rates associated with higher mastectomy rates
One of the goals of screening mammography is to detect breast cancer earlier to allow more women to undergo breast conserving surgery (lumpectomy) instead of mastectomy. A recent study in Norway found the opposite to be true.
The study compared breast surgery rates before and after the implementation of a breast screening program and rates between those invited for screening and those not. Screening was associated with an increase in all breast surgery (lumpectomy plus mastectomy) and an increase in mastectomy rates.
A September 13 story in US News and World Report/HealthDay noted that the study did not investigate why mastectomy rates climbed. Possible reasons include overdiagnosis (detecting and treating tumors that might never have posed a risk), poor access to radiation centers (making mastectomy a safer option), improved breast reconstruction techniques (making mastectomy a less "dreadful" choice) and patient decision to undergo more aggressive treatment due to recurrence fears.
BPA may interfere with tamoxifen
There may be another reason to avoid bisphenol-A (BPA). BPAs, which are used to make plastics, have been associated with a variety of health concerns. According to recent study in cells, BPA may not only increase the risk of developing breast cancer, may also interfere with tamoxifen therapy. (Link to the study.)
On September 13, the San Francisco Chronicle covered the study. In the lab, when non-cancerous cells from high-risk patients were exposed to BPA, they started to behave like cancer cells. When these BPA-exposed cells were exposed to tamoxifen, they continued to grow. "The study found that healthy cells exposed to BPA and methylparaben started figuring out ways to bypass drugs like tamoxifen."
Avoiding BPA may not be easy. According to Dr. William Goodson, lead study author, ""It's used so much. We kind of swim in it." Still, efforts to ban BPAs are underway. A current bill (AB1319) on the governor's desk would ban BPA in sippy cups and baby bottles in California.
At LATESTBreastCancer.com, we'll continue to follow the latest breast cancer news and research. You may access links to news articles, medical journal abstracts and FDA information on every breast cancer test and treatment option on our website anytime.
Effexor and Catapres effective for hot flashes
Some breast cancer treatments may induce menopause and cause unpleasant side effects such as hot flashes. A September 12 study in the Journal of Clinical Oncology compared Effexor (venlafaxine) to Catapres (clonidine) to a placebo for the treatment of hot flashes in breast cancer patients.
Both Effexor and Catapres were found to be effective in the management of hot flashes. Effexor resulted in a more immediate reduction in hot flashes, but at week 12, hot flashes were lower in the Catapres group. Reports of nausea, constipation and appetite loss were higher in the Effexor group.
A September 12 Family Practice News report on the study included a commentary which noted that the small size of the study was its "main weakness." In the end, only 35 patients took Effexor, 28 Catapres and 17 the placebo. A larger study would be needed to "reliably identify suspected differences between the study arms." Also, the study authors noted that the duration of the study may have been too short to adequately assess side effects.
Nonetheless, in the Family Practice News story, study authors said the "more rapid reduction in hot flashes suggests that venlafaxine is to be preferred over clonidine." They advised 37.5 mg daily in the first week, increasing to 75 mg "if greater efficacy is desired."
Fatigue after treatment associated with pain and depression
Last week EurekAlert! and the UPI covered a study from Spain on fatigue in breast cancer survivors. The study found that patients most affected by fatigue also suffered "episodes of depression, body image deterioration, neck and shoulder pain, and limited arm movement, possibly due to the surgical intervention," such as breast conserving surgery (lumpectomy) and mastectomy.
The lead author noted that these findings should "motivate" patient support programs to provide resources to improve psychological states and pain to improve fatigue.
Higher mammography rates associated with higher mastectomy rates
One of the goals of screening mammography is to detect breast cancer earlier to allow more women to undergo breast conserving surgery (lumpectomy) instead of mastectomy. A recent study in Norway found the opposite to be true.
The study compared breast surgery rates before and after the implementation of a breast screening program and rates between those invited for screening and those not. Screening was associated with an increase in all breast surgery (lumpectomy plus mastectomy) and an increase in mastectomy rates.
A September 13 story in US News and World Report/HealthDay noted that the study did not investigate why mastectomy rates climbed. Possible reasons include overdiagnosis (detecting and treating tumors that might never have posed a risk), poor access to radiation centers (making mastectomy a safer option), improved breast reconstruction techniques (making mastectomy a less "dreadful" choice) and patient decision to undergo more aggressive treatment due to recurrence fears.
BPA may interfere with tamoxifen
There may be another reason to avoid bisphenol-A (BPA). BPAs, which are used to make plastics, have been associated with a variety of health concerns. According to recent study in cells, BPA may not only increase the risk of developing breast cancer, may also interfere with tamoxifen therapy. (Link to the study.)
On September 13, the San Francisco Chronicle covered the study. In the lab, when non-cancerous cells from high-risk patients were exposed to BPA, they started to behave like cancer cells. When these BPA-exposed cells were exposed to tamoxifen, they continued to grow. "The study found that healthy cells exposed to BPA and methylparaben started figuring out ways to bypass drugs like tamoxifen."
Avoiding BPA may not be easy. According to Dr. William Goodson, lead study author, ""It's used so much. We kind of swim in it." Still, efforts to ban BPAs are underway. A current bill (AB1319) on the governor's desk would ban BPA in sippy cups and baby bottles in California.
At LATESTBreastCancer.com, we'll continue to follow the latest breast cancer news and research. You may access links to news articles, medical journal abstracts and FDA information on every breast cancer test and treatment option on our website anytime.
Thursday, September 1, 2011
Breast Cancer News Weekly Wrap-Up (Aug. 28 to Sept. 1)
What's new in breast cancer news? Today we'll share the week's headlines and the studies behind them.
US News and World Report: "Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study"
This headline sounds encouraging. For hormone receptor positive breast cancer, hormonal therapy is typically prescribed for five years and associated with unpleasant side effects. Who wouldn't want to skip it?
However, there is some fine print. (Links to the US News and World Report/HealthDay story, the underlying study and related Memo to the Media may be found on the Arimidex (anastrozole) page of our website.)
The August 31 Journal of the National Cancer Institute (JNCI) study evaluated mortality (death) rates for women in Denmark with early-stage, node-negative, hormone-receptor positive breast cancer. Women over 60, with small tumors (up to 10mm), who received no hormonal therapy or chemotherapy were not at an increased risk of death compared with women the same age in the general population.
In an accompanying editorial, the authors noted that even if there is no benefit in terms of mortality, hormonal therapy reduces the risk of recurrence in the same or opposite breast, and many "will continue to take it for that reason." (See the JNCI Memo to the Media under the News tab.)
For women in this subset, this study is another factor to be considered in the decision on whether to take hormonal therapy. According to the Memo to the Media, "patient preferences regarding risks and benefits play a critical role" in the decision. In US News and World Report, Dr. Jennifer Griggs, a study co-author, suggested a three month trial of hormone therapy to gauge side effects before deciding whether to continue.
Reuters: "New breast cancer gene may help predict risk"
The gene at issue, known as CHEK2, is not really new. The CHEK2 genetic test is available, but not generally offered. Instead, BRCA 1/2 genetic tests are typically used to assess hereditary risk. (More on the test and links to the study and story below may be found on the CHEK 2 gene testing page of our website.)
The August 29 Journal of Clinical Oncology study from Poland estimated breast cancer risk in women with CHEK2 mutations and family histories of breast cancer. Baseline lifetime risk was assumed to be 6%. Women with a CHEK2 mutation and no family history had an estimated lifetime risk of 20%. Risk increased with family history. A second-degree relative with breast cancer raised the risk to 28%, one first-degree relative to 34% and both a first- and second-degree relative to 44%.
An August 29 story in Reuters noted that the study may not be "ready for prime time yet." According to Reuters, Dr. James P. Evans, editor-in-chief of Genetics in Medicine, called the study a "nice start," but said it would be "premature" to recommend CHEK2 testing for everyone with a family history now. Dr. Diana Petitti, of Arizona State University in Phoenix, said the study is "an important breakthrough," but more research is needed, noting that "this is a field where replication is critical."
One of the concerns is that the Polish women in the study may be different than Americans. In America, the lifetime risk of breast cancer is about 12% (1 in 8). According to the study authors, that number is only about 6 percent in Poland.
ScienceDaily.com: "Breast Cancer Risk Drops When Diet Includes Walnuts, Researchers Find"
A recent study in Nutrition and Cancer found that walnut consumption reduced breast cancer risk in mice. Study leader Elaine Hardman, Ph.D was quoted in ScienceDaily.com to say, "The results of this study indicate that increased consumption of walnut could be part of a healthy diet and reduce risk for cancer in future generations." (Link on the the Fruits, Vegetables and Nuts page of our website.)
Animals studies such as this one are often interesting, but the applicability in humans has not yet been proven in human trials.
Toronto Sun: "Smoking after menopause could increase risk for breast cancer: Study"
This week, the Toronto Sun, US News and World Report/HealthDay and WebMD covered an August 10 study in The Journal of Endocrinology and Metabolism which found higher androgen and estrogen levels in smokers.
According to the study, because hormone levels dropped with smoking cessation, "hormone related disease risks could potentially be modified by changing smoking habits."
Next week, we'll share the latest research on soy for breast cancer survivors. Until then, all the latest news and research on any breast cancer test or treatment option may be found on the treatment pages of the LATESTBreastCancer.com website.
US News and World Report: "Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study"
This headline sounds encouraging. For hormone receptor positive breast cancer, hormonal therapy is typically prescribed for five years and associated with unpleasant side effects. Who wouldn't want to skip it?
However, there is some fine print. (Links to the US News and World Report/HealthDay story, the underlying study and related Memo to the Media may be found on the Arimidex (anastrozole) page of our website.)
The August 31 Journal of the National Cancer Institute (JNCI) study evaluated mortality (death) rates for women in Denmark with early-stage, node-negative, hormone-receptor positive breast cancer. Women over 60, with small tumors (up to 10mm), who received no hormonal therapy or chemotherapy were not at an increased risk of death compared with women the same age in the general population.
In an accompanying editorial, the authors noted that even if there is no benefit in terms of mortality, hormonal therapy reduces the risk of recurrence in the same or opposite breast, and many "will continue to take it for that reason." (See the JNCI Memo to the Media under the News tab.)
For women in this subset, this study is another factor to be considered in the decision on whether to take hormonal therapy. According to the Memo to the Media, "patient preferences regarding risks and benefits play a critical role" in the decision. In US News and World Report, Dr. Jennifer Griggs, a study co-author, suggested a three month trial of hormone therapy to gauge side effects before deciding whether to continue.
Reuters: "New breast cancer gene may help predict risk"
The gene at issue, known as CHEK2, is not really new. The CHEK2 genetic test is available, but not generally offered. Instead, BRCA 1/2 genetic tests are typically used to assess hereditary risk. (More on the test and links to the study and story below may be found on the CHEK 2 gene testing page of our website.)
The August 29 Journal of Clinical Oncology study from Poland estimated breast cancer risk in women with CHEK2 mutations and family histories of breast cancer. Baseline lifetime risk was assumed to be 6%. Women with a CHEK2 mutation and no family history had an estimated lifetime risk of 20%. Risk increased with family history. A second-degree relative with breast cancer raised the risk to 28%, one first-degree relative to 34% and both a first- and second-degree relative to 44%.
An August 29 story in Reuters noted that the study may not be "ready for prime time yet." According to Reuters, Dr. James P. Evans, editor-in-chief of Genetics in Medicine, called the study a "nice start," but said it would be "premature" to recommend CHEK2 testing for everyone with a family history now. Dr. Diana Petitti, of Arizona State University in Phoenix, said the study is "an important breakthrough," but more research is needed, noting that "this is a field where replication is critical."
One of the concerns is that the Polish women in the study may be different than Americans. In America, the lifetime risk of breast cancer is about 12% (1 in 8). According to the study authors, that number is only about 6 percent in Poland.
ScienceDaily.com: "Breast Cancer Risk Drops When Diet Includes Walnuts, Researchers Find"
A recent study in Nutrition and Cancer found that walnut consumption reduced breast cancer risk in mice. Study leader Elaine Hardman, Ph.D was quoted in ScienceDaily.com to say, "The results of this study indicate that increased consumption of walnut could be part of a healthy diet and reduce risk for cancer in future generations." (Link on the the Fruits, Vegetables and Nuts page of our website.)
Animals studies such as this one are often interesting, but the applicability in humans has not yet been proven in human trials.
Toronto Sun: "Smoking after menopause could increase risk for breast cancer: Study"
This week, the Toronto Sun, US News and World Report/HealthDay and WebMD covered an August 10 study in The Journal of Endocrinology and Metabolism which found higher androgen and estrogen levels in smokers.
According to the study, because hormone levels dropped with smoking cessation, "hormone related disease risks could potentially be modified by changing smoking habits."
Next week, we'll share the latest research on soy for breast cancer survivors. Until then, all the latest news and research on any breast cancer test or treatment option may be found on the treatment pages of the LATESTBreastCancer.com website.
Wednesday, August 24, 2011
Breast Cancer News (8/24): Aromatase Inhibitors and Tamoxifen
Tamoxifen or aromatase inhibitors? It's a treatment decision for postmenopausal women with hormone-receptor positive breast cancer. Three recent studies compared tamoxifen to aromatase inhibitors in terms of survival, toxicity and tumor activity. Links to all studies and media coverage may be found on the Arimidex page of the LATESTBreastCancer.com website.
Adjuvant therapy: Aromatase inhibitor toxicity and overall survival
When used as adjuvant therapy to prevent recurrence, aromatase inhibitors (AIs) are associated with improvements in disease-free survival, but not overall survival. A review in the Journal of the National Cancer Institute, first published online July 8, examined whether differences in toxicity explain the difference in overall survival. Yesterday, Medical News Today and medpagetoday.com covered the results.
The review included 7 trials and 30,023 patients. Longer use of AIs was associated with increased odds of cardiovascular disease and bone fractures, but decreased odds of venous thrombosis and endometrial cancer. Five years of AIs was associated with an increase in the odds of death without breast cancer recurrence compared to 5 years of tamoxifen or 2-3 years of tamoxifen followed by AIs. However, the difference was not statistically significant.
The authors concluded that when used alone, "cumulative toxicity" of AIs may explain the lack of overall survival benefit despite improvement in disease-free survival. Switching from tamoxifen to AIs "reduces this toxicity and is likely the best balance between efficacy and toxicity."
Advanced breast cancer: Aromatase inhibitors vs. tamoxifen
A review in Clinical Breast Cancer, first published online July 7, compared aromatase inhibitors to tamoxifen as first-line therapy to treat advanced breast cancer. The review included 6 trials with 2,560 patients. Aromatase inhibitors had a significantly better overall response rate and clinical benefit. There was a trend towards improved overall survival, but it was not statistically significant. Toxicities did not differ significantly, except vaginal bleeding and thromboembolic events.
The authors concluded that AIs "appeared to be effective and feasible compared with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer." They noted that further, randomized, controlled trials are necessary.
PET scanning reveals differences in anti-estrogen activity
How effective is hormonal therapy in blocking estrogen activity?
A July 15 Clinical Cancer Research study used PET scanning to monitor how tumors in metastatic patients responded to tamoxifen, Faslodex (fulvestrant) and aromatase inhibitors such as Arimidex, Aromasin or Femara. This week, DOTMed News and Medical News Today covered the study.
Thirty women with metastatic breast cancer underwent PET scan imaging. Uptake of an estrogen-containing contrast agent was used to assess estrogen binding. A decline in uptake meant less estrogen binding. Tumor uptake "declined more markedly" with tamoxifen and Faslodex than with aromatase inhibitors. Tamoxifen was more effective than Fulvestrant in complete tumor blockade of estrogen.
The authors concluded that PET scanning "can assess" the pharmacodynamics (what a drug does to a body) and "give insight" into the activity of estrogen-receptor targeted agents. "Imaging revealed significant differences between agents," including differences in blockade.
Dr. Hannah Linden, a study author, was quoted in both media stories to say, "What we're suggesting in the paper . . . is if estrogen is incompletely blocked you're not getting a good outcome for the patient."
We'll continue to follow hormone therapy research. We review medical journal abstracts and media sources daily. All the latest news and research on any breast cancer test or treatment option may be found on the treatment pages of the LATESTBreastCancer.com website anytime.
Adjuvant therapy: Aromatase inhibitor toxicity and overall survival
When used as adjuvant therapy to prevent recurrence, aromatase inhibitors (AIs) are associated with improvements in disease-free survival, but not overall survival. A review in the Journal of the National Cancer Institute, first published online July 8, examined whether differences in toxicity explain the difference in overall survival. Yesterday, Medical News Today and medpagetoday.com covered the results.
The review included 7 trials and 30,023 patients. Longer use of AIs was associated with increased odds of cardiovascular disease and bone fractures, but decreased odds of venous thrombosis and endometrial cancer. Five years of AIs was associated with an increase in the odds of death without breast cancer recurrence compared to 5 years of tamoxifen or 2-3 years of tamoxifen followed by AIs. However, the difference was not statistically significant.
The authors concluded that when used alone, "cumulative toxicity" of AIs may explain the lack of overall survival benefit despite improvement in disease-free survival. Switching from tamoxifen to AIs "reduces this toxicity and is likely the best balance between efficacy and toxicity."
Advanced breast cancer: Aromatase inhibitors vs. tamoxifen
A review in Clinical Breast Cancer, first published online July 7, compared aromatase inhibitors to tamoxifen as first-line therapy to treat advanced breast cancer. The review included 6 trials with 2,560 patients. Aromatase inhibitors had a significantly better overall response rate and clinical benefit. There was a trend towards improved overall survival, but it was not statistically significant. Toxicities did not differ significantly, except vaginal bleeding and thromboembolic events.
The authors concluded that AIs "appeared to be effective and feasible compared with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer." They noted that further, randomized, controlled trials are necessary.
PET scanning reveals differences in anti-estrogen activity
How effective is hormonal therapy in blocking estrogen activity?
A July 15 Clinical Cancer Research study used PET scanning to monitor how tumors in metastatic patients responded to tamoxifen, Faslodex (fulvestrant) and aromatase inhibitors such as Arimidex, Aromasin or Femara. This week, DOTMed News and Medical News Today covered the study.
Thirty women with metastatic breast cancer underwent PET scan imaging. Uptake of an estrogen-containing contrast agent was used to assess estrogen binding. A decline in uptake meant less estrogen binding. Tumor uptake "declined more markedly" with tamoxifen and Faslodex than with aromatase inhibitors. Tamoxifen was more effective than Fulvestrant in complete tumor blockade of estrogen.
The authors concluded that PET scanning "can assess" the pharmacodynamics (what a drug does to a body) and "give insight" into the activity of estrogen-receptor targeted agents. "Imaging revealed significant differences between agents," including differences in blockade.
Dr. Hannah Linden, a study author, was quoted in both media stories to say, "What we're suggesting in the paper . . . is if estrogen is incompletely blocked you're not getting a good outcome for the patient."
We'll continue to follow hormone therapy research. We review medical journal abstracts and media sources daily. All the latest news and research on any breast cancer test or treatment option may be found on the treatment pages of the LATESTBreastCancer.com website anytime.
Monday, August 22, 2011
Breast Cancer News (8/22): Drug Shortage, Hot Flashes and Gifts for Mastectomy Patients
Today in breast cancer news, there are stories on the government response to the drug shortage, the use of hormone replacement therapy to treat hot flashes and a great piece on gifts for mastectomy patients. Interestingly, all of today's stories are from the New York Times.
The US considers interventions in response to the drug shortage
The chemotherapy drug shortage is real. A LATESTBreastCancer.com subscriber recently shared that she was unable to receive her last infusion of Taxol (paclitaxel). She was given another, similar drug instead. (She shares her experience in her blog.)
Last week, USA Today ran a story on price gouging due to the shortage.
On Friday, the New York Times wrote about government plans for intervention. (Link may be found on the Taxol page of our website.) Proposals include a national stockpile of cancer drugs, a nonprofit to manage drug import and manufacture, mandatory early warnings of shortages and increased inspections of foreign plants.
In the meantime, concern and prices are soaring. Dr. Michael Link, president of the American Society of Clinical Oncology, was quoted in the New York Times, "These shortages are just killing us." “These drugs save lives, and it’s unconscionable that medicines that cost a couple of bucks a vial are unavailable.”
Hot flashes, hormone replacement therapy and breast cancer risk
Is hormone replacement therapy, which has been associated with an increased risk of breast cancer, still an option to treat hot flashes during menopause?
An August 15 blog in the New York Times suggests it should be for some. For women with severe symptoms, hormone replacement is effective. Alternative remedies such as soy and flaxseed have been disappointing in clinical trial.
According to the article, some doctors are frustrated by the message that women must seek alternative treatment. They believe risk of breast cancer should be factored into the decision like any other treatment side-effect. For some women, the benefits of hormone replacement would outweigh the risks.
Back in May, the Los Angeles Times ran a similar piece. Dr. Richard Santen, the endocrinologist interviewed, clarified that studies on breast cancer risk have involved women in their 60s. For women in their 50s, who have had a hysterectomy, estrogen alone may be taken to treat symptoms of menopause. For women with a low personal risk of breast cancer, taking estrogen and progesterone results in a potential breast cancer risk which is "also quite low." On the other hand, women with a family history of breast cancer and high personal risk should not take estrogen plus progesterone. He concluded, "We've got to individualize the therapy to the individual patient."
Gifts for mastectomy patients
"What gifts bring the most comfort to breast surgery patients?" Last week, the New York Times shared an entry from the Losing My Boobs blog with terrific suggestions for gifts for mastectomy patients. It's a must read for women facing surgery and her friends and family.
Please check back tomorrow for more breast cancer news and research updates. Until then, all news and research on any breast cancer test or treatment option may be found on the LATESTBreastCancer.com website.
The US considers interventions in response to the drug shortage
The chemotherapy drug shortage is real. A LATESTBreastCancer.com subscriber recently shared that she was unable to receive her last infusion of Taxol (paclitaxel). She was given another, similar drug instead. (She shares her experience in her blog.)
Last week, USA Today ran a story on price gouging due to the shortage.
On Friday, the New York Times wrote about government plans for intervention. (Link may be found on the Taxol page of our website.) Proposals include a national stockpile of cancer drugs, a nonprofit to manage drug import and manufacture, mandatory early warnings of shortages and increased inspections of foreign plants.
In the meantime, concern and prices are soaring. Dr. Michael Link, president of the American Society of Clinical Oncology, was quoted in the New York Times, "These shortages are just killing us." “These drugs save lives, and it’s unconscionable that medicines that cost a couple of bucks a vial are unavailable.”
Hot flashes, hormone replacement therapy and breast cancer risk
Is hormone replacement therapy, which has been associated with an increased risk of breast cancer, still an option to treat hot flashes during menopause?
An August 15 blog in the New York Times suggests it should be for some. For women with severe symptoms, hormone replacement is effective. Alternative remedies such as soy and flaxseed have been disappointing in clinical trial.
According to the article, some doctors are frustrated by the message that women must seek alternative treatment. They believe risk of breast cancer should be factored into the decision like any other treatment side-effect. For some women, the benefits of hormone replacement would outweigh the risks.
Back in May, the Los Angeles Times ran a similar piece. Dr. Richard Santen, the endocrinologist interviewed, clarified that studies on breast cancer risk have involved women in their 60s. For women in their 50s, who have had a hysterectomy, estrogen alone may be taken to treat symptoms of menopause. For women with a low personal risk of breast cancer, taking estrogen and progesterone results in a potential breast cancer risk which is "also quite low." On the other hand, women with a family history of breast cancer and high personal risk should not take estrogen plus progesterone. He concluded, "We've got to individualize the therapy to the individual patient."
Gifts for mastectomy patients
"What gifts bring the most comfort to breast surgery patients?" Last week, the New York Times shared an entry from the Losing My Boobs blog with terrific suggestions for gifts for mastectomy patients. It's a must read for women facing surgery and her friends and family.
Please check back tomorrow for more breast cancer news and research updates. Until then, all news and research on any breast cancer test or treatment option may be found on the LATESTBreastCancer.com website.
Tuesday, August 16, 2011
Breast Cancer News (8/16): A little something for everyone
Today's breast cancer news update has a little something for everyone. For women in treatment, there's a story on tamoxifen, an overview of DCIS treatment options and an update on a vaccine in development. For women who have completed treatment, there are stories on fatigue and post-trauma survival. Of general interest, there are pieces on the biology of cancer cells and breast cancer statistics in South Chicago.
BREAST CANCER NEWS FOR WOMEN IN TREATMENT
Tamoxifen affected by genetic mutations and anti-depressants
Yesterday, CBS News Miami published a story and video explaining why tamoxifen may not be effective in some women. Mutations in CYP2D6 genes and anti-depressants, such as Zoloft and Prozac, may interfere with tamoxifen metabolism. Interestingly, the story notes that a "hint" that tamoxifen may not be working is the absence of hot flashes.
An overview of DCIS treatment options
In a commentary, "Management of DCIS - A Work in Progress," cancernetwork.com reviewed the latest treatment options for DCIS. In addition to standard options such as breast conserving surgery (lumpectomy) or mastectomy, the article addresses prognostic factors and a future role for molecular markers, such as HER2 status.
Plans for phase III vaccine trial make progress
In a GlobeNewswire press release, RXi Pharmaceuticals announced progress in its plans for a phase III trial of its NeuVax vaccine to prevent recurrence in early-stage, node-positive breast cancer with low to intermediate HER2 expression. A principal investigator has been named, conditional site approvals have been received, an organization has been selected to manage international centers and manufacturing approvals have been submitted. The trial is expected to commence in the first half of 2012.
BREAST CANCER NEWS FOR WOMEN WHO HAVE COMPLETED TREATMENT
Stress and growth after the trauma of breast cancer
After the stress of breast cancer diagnosis and treatment, some women experience post-traumatic stress disorder (PTSD). BreastCancer.org provides an overview of symptoms and management suggestions.
Yesterday, an article in the Philadelphia Inquirer explored studies on "the positive side of trauma and grief." For some women, experiencing a trauma such as breast cancer results in personal growth. The "key quality" for post-traumatic growth appears to be "expressive flexibility," the ability to express or suppress emotions as necessary. Experts caution that it is "bad to expect growth." The last thing patients need is more pressure.
Biofield therapy to treat fatigue in breast cancer survivors
Breast cancer survivors often battle fatigue. HemOnc Today wrote about a recent study in Cancer on the complementary therapy known as biofield healing. Basically, a biofield is believed to be the energy or aura that surrounds a person. In the study, biofield healing and mock healing both significantly reduced fatigue compared to wait-list controls. Only biofield therapy made a significant difference in cortisol slope. Because both biofield and mock therapy improved fatigue, the results may be partially due to "nonspecific factors," such as scheduled rest, touch and clinical intervention. However, because biofield healing had a greater effect on general and mental fatigue, the authors note that further study is warranted.
BREAST CANCER NEWS OF GENERAL INTEREST
How breast cancer cells evade natural killer cells
In a healthy immune system, natural killer (NK) cells exhibit anti-tumor activity. In breast cancer, tumor cells and the surrounding microenvironment develop the ability to escape NK cell antitumor immunity. The biological process is explained in a GEN: Genetic Engineering & Biotechnology News story on a recent study in The Journal of Clinical Investigation.
Breast cancer mortality rates in South Chicago
Yesterday, a story in the Chicago Sun Times revealed that Chicago's south and southwest side neighborhoods are the "unhealthiest in the city." Those areas had the highest breast cancer mortality rates and few breast health services. Neighborhoods in the north and northwest have more breast health resources and the lowest breast cancer mortality rates. Dr. Bechara Choucair, Chicago's commissioner of health, noted that black women are less likely to get breast cancer, but more likely to die from it. He said the focus "needs to be on making sure black women have more access to mammography, better quality mammography and more timely treatment."
Please check back tomorrow for more breast cancer news highlights from LATESTBreastCancer.com.
BREAST CANCER NEWS FOR WOMEN IN TREATMENT
Tamoxifen affected by genetic mutations and anti-depressants
Yesterday, CBS News Miami published a story and video explaining why tamoxifen may not be effective in some women. Mutations in CYP2D6 genes and anti-depressants, such as Zoloft and Prozac, may interfere with tamoxifen metabolism. Interestingly, the story notes that a "hint" that tamoxifen may not be working is the absence of hot flashes.
An overview of DCIS treatment options
In a commentary, "Management of DCIS - A Work in Progress," cancernetwork.com reviewed the latest treatment options for DCIS. In addition to standard options such as breast conserving surgery (lumpectomy) or mastectomy, the article addresses prognostic factors and a future role for molecular markers, such as HER2 status.
Plans for phase III vaccine trial make progress
In a GlobeNewswire press release, RXi Pharmaceuticals announced progress in its plans for a phase III trial of its NeuVax vaccine to prevent recurrence in early-stage, node-positive breast cancer with low to intermediate HER2 expression. A principal investigator has been named, conditional site approvals have been received, an organization has been selected to manage international centers and manufacturing approvals have been submitted. The trial is expected to commence in the first half of 2012.
BREAST CANCER NEWS FOR WOMEN WHO HAVE COMPLETED TREATMENT
Stress and growth after the trauma of breast cancer
After the stress of breast cancer diagnosis and treatment, some women experience post-traumatic stress disorder (PTSD). BreastCancer.org provides an overview of symptoms and management suggestions.
Yesterday, an article in the Philadelphia Inquirer explored studies on "the positive side of trauma and grief." For some women, experiencing a trauma such as breast cancer results in personal growth. The "key quality" for post-traumatic growth appears to be "expressive flexibility," the ability to express or suppress emotions as necessary. Experts caution that it is "bad to expect growth." The last thing patients need is more pressure.
Biofield therapy to treat fatigue in breast cancer survivors
Breast cancer survivors often battle fatigue. HemOnc Today wrote about a recent study in Cancer on the complementary therapy known as biofield healing. Basically, a biofield is believed to be the energy or aura that surrounds a person. In the study, biofield healing and mock healing both significantly reduced fatigue compared to wait-list controls. Only biofield therapy made a significant difference in cortisol slope. Because both biofield and mock therapy improved fatigue, the results may be partially due to "nonspecific factors," such as scheduled rest, touch and clinical intervention. However, because biofield healing had a greater effect on general and mental fatigue, the authors note that further study is warranted.
BREAST CANCER NEWS OF GENERAL INTEREST
How breast cancer cells evade natural killer cells
In a healthy immune system, natural killer (NK) cells exhibit anti-tumor activity. In breast cancer, tumor cells and the surrounding microenvironment develop the ability to escape NK cell antitumor immunity. The biological process is explained in a GEN: Genetic Engineering & Biotechnology News story on a recent study in The Journal of Clinical Investigation.
Breast cancer mortality rates in South Chicago
Yesterday, a story in the Chicago Sun Times revealed that Chicago's south and southwest side neighborhoods are the "unhealthiest in the city." Those areas had the highest breast cancer mortality rates and few breast health services. Neighborhoods in the north and northwest have more breast health resources and the lowest breast cancer mortality rates. Dr. Bechara Choucair, Chicago's commissioner of health, noted that black women are less likely to get breast cancer, but more likely to die from it. He said the focus "needs to be on making sure black women have more access to mammography, better quality mammography and more timely treatment."
Please check back tomorrow for more breast cancer news highlights from LATESTBreastCancer.com.
Monday, August 1, 2011
Breast Cancer News (8/1): Tamoxifen, Screening and Race
Deja vu in breast cancer news? Didn't we discuss tamoxifen, screening mammography and race last week? Although the topics seem familiar, today's studies approach these issues from different directions.
Long-term efficacy of tamoxifen to prevent recurrence
Last week, we highlighted a study on the side effects of tamoxifen when used to prevent breast cancer (July 29 blog.) Today, we'll look at the latest research on adjuvant tamoxifen to prevent breast cancer recurrence. Links to the studies and news below may be found on the tamoxifen page of our website.
Back in March, a Journal of Clinical Oncology study found that, for women over 50, 5 years of tamoxifen reduced the risk of recurrence 15 years after starting treatment. It also reduced the risk of cardiovascular disease and death. US News and World Report/HealthDay, Vancouver Sun and Medical News Today all covered the study.
On Friday, a review in The Lancet Oncology analyzed patient data from 20 trials of tamoxifen. The simple conclusion was that "5 years of adjuvant tamoxifen safely reduces 15-year risks of breast cancer recurrence and death" for women with estrogen receptor positive breast cancer. Media coverage included stories in US News and World Report/HealthDay and Medical News Today and a written story and video by ABC News.
The study, however, was anything but simple. It was a complex statistical analysis, which considered the risk of fatal side effects, variations in estrogen receptor status, risk by time period and absolute risks without tamoxifen.
Kathleen Kolb, author of the AccidentalAmazon.com blog, read the full text of the study with a critical eye. Her piece, Tamoxifen Efficacy Revisited: Behind The Hype delves into the details of the statistical findings in search of practical meaning. For those interested in adjuvant tamoxifen, her analysis is an additional resource.
More fuel in the screening mammography debate
Last week, we looked at a study on mammography and the use of computer-aided detection (July 28 blog). This week, a British Medical Journal study evaluated whether screening mammography affects mortality, adding more fuel to the debate on when to start and how often to have a screening mammogram.
What's the issue? In one corner, advocates of yearly screening starting at age 40 argue that early detection saves lives. In the other corner, opponents argue that for women in their 40s with average risk, the benefits of annual screening mammography are small and not worth the exposure to radiation and high rates of false positives, which result in higher anxiety and unnecessary follow-up procedures. They question the relationship between screening mammography and breast cancer mortality.
There is research to support both sides. The screening mammography page of our website has many pages of news and study links. Recently, a June 28 Swedish study in Radiology found that an invitation to screening mammography resulted in a "highly significant decrease in breast cancer-specific mortality."
The July 28 British Medical Journal study reached an opposite conclusion. (Follow the link for the full text of the study.) The study compared breast cancer mortality rates for pairs of European countries which implemented breast cancer screening programs at different times. Using World Health Organization (WHO) data, the analysis suggested that "screening did not play a direct part in the reductions of breast cancer mortality." US News and World Report/HealthDay and Reuters both covered the study.
We'll continue to follow the controversy and highlight the latest research.
Racial differences in receipt of breast cancer treatment
On July 26, we discussed three studies which failed to explain why African American women with advanced breast cancer tend to have a worse prognosis than Caucasian women. On July 29, Reuters covered a July 15 study in Cancer which approached this issue from a different angle.
The study authors acknowledged the racial difference in mortality rates and examined if there were racial differences in treatment received by women with the same health insurance. The women in the study were all covered by the Department of Defense Military Health System. Results showed no statistical difference in type of surgery received - mastectomy or breast conserving surgery plus radiation. For women with "local stage tumors," African Americans were just as likely as Caucasians to receive chemotherapy and hormonal therapy. However, for women with "regional stage tumors," or advanced breast cancer, African Americans were significantly less likely than Caucasians to receive chemotherapy and hormonal therapy.
Questions remain as to why the treatments were different. Were the options not offered? Were they offered and rejected? Further studies are needed to address the disparity.
Please check back tomorrow for more breast cancer news and research updates from LATESTBreastCancer.com. As always, all the latest news and research on any breast cancer test, treatment option or complementary therapy may be found on the treatment pages of our website anytime.
Long-term efficacy of tamoxifen to prevent recurrence
Last week, we highlighted a study on the side effects of tamoxifen when used to prevent breast cancer (July 29 blog.) Today, we'll look at the latest research on adjuvant tamoxifen to prevent breast cancer recurrence. Links to the studies and news below may be found on the tamoxifen page of our website.
Back in March, a Journal of Clinical Oncology study found that, for women over 50, 5 years of tamoxifen reduced the risk of recurrence 15 years after starting treatment. It also reduced the risk of cardiovascular disease and death. US News and World Report/HealthDay, Vancouver Sun and Medical News Today all covered the study.
On Friday, a review in The Lancet Oncology analyzed patient data from 20 trials of tamoxifen. The simple conclusion was that "5 years of adjuvant tamoxifen safely reduces 15-year risks of breast cancer recurrence and death" for women with estrogen receptor positive breast cancer. Media coverage included stories in US News and World Report/HealthDay and Medical News Today and a written story and video by ABC News.
The study, however, was anything but simple. It was a complex statistical analysis, which considered the risk of fatal side effects, variations in estrogen receptor status, risk by time period and absolute risks without tamoxifen.
Kathleen Kolb, author of the AccidentalAmazon.com blog, read the full text of the study with a critical eye. Her piece, Tamoxifen Efficacy Revisited: Behind The Hype delves into the details of the statistical findings in search of practical meaning. For those interested in adjuvant tamoxifen, her analysis is an additional resource.
More fuel in the screening mammography debate
Last week, we looked at a study on mammography and the use of computer-aided detection (July 28 blog). This week, a British Medical Journal study evaluated whether screening mammography affects mortality, adding more fuel to the debate on when to start and how often to have a screening mammogram.
What's the issue? In one corner, advocates of yearly screening starting at age 40 argue that early detection saves lives. In the other corner, opponents argue that for women in their 40s with average risk, the benefits of annual screening mammography are small and not worth the exposure to radiation and high rates of false positives, which result in higher anxiety and unnecessary follow-up procedures. They question the relationship between screening mammography and breast cancer mortality.
There is research to support both sides. The screening mammography page of our website has many pages of news and study links. Recently, a June 28 Swedish study in Radiology found that an invitation to screening mammography resulted in a "highly significant decrease in breast cancer-specific mortality."
The July 28 British Medical Journal study reached an opposite conclusion. (Follow the link for the full text of the study.) The study compared breast cancer mortality rates for pairs of European countries which implemented breast cancer screening programs at different times. Using World Health Organization (WHO) data, the analysis suggested that "screening did not play a direct part in the reductions of breast cancer mortality." US News and World Report/HealthDay and Reuters both covered the study.
We'll continue to follow the controversy and highlight the latest research.
Racial differences in receipt of breast cancer treatment
On July 26, we discussed three studies which failed to explain why African American women with advanced breast cancer tend to have a worse prognosis than Caucasian women. On July 29, Reuters covered a July 15 study in Cancer which approached this issue from a different angle.
The study authors acknowledged the racial difference in mortality rates and examined if there were racial differences in treatment received by women with the same health insurance. The women in the study were all covered by the Department of Defense Military Health System. Results showed no statistical difference in type of surgery received - mastectomy or breast conserving surgery plus radiation. For women with "local stage tumors," African Americans were just as likely as Caucasians to receive chemotherapy and hormonal therapy. However, for women with "regional stage tumors," or advanced breast cancer, African Americans were significantly less likely than Caucasians to receive chemotherapy and hormonal therapy.
Questions remain as to why the treatments were different. Were the options not offered? Were they offered and rejected? Further studies are needed to address the disparity.
Please check back tomorrow for more breast cancer news and research updates from LATESTBreastCancer.com. As always, all the latest news and research on any breast cancer test, treatment option or complementary therapy may be found on the treatment pages of our website anytime.
Friday, July 29, 2011
Breast Cancer News for July 29: Risk, Prevention and Screening
Breast cancer research news is not always about breast cancer treatment. Today, we'll examine the latest data on breast cancer in America and highlight the latest breast cancer research on risk and prevention.
U.S. breast cancer incidence rates vary by estrogen receptor status
Yesterday, msnbc.com, citing a Journal of the National Cancer Institute study, revealed that although American breast cancer incidence rates appear to be stable, rates of estrogen-receptor negative breast cancer are actually falling and rates of estrogen-receptor positive breast cancer are on the rise. The decline in ER-negative breast cancer, which is more difficult to treat, is good news. The rise in ER-positive tumors, however, is concerning, and will likely be the focus of future research on risk and prevention.
Three new risk studies: fiber, breast density and BRCA biology
According to Reuters, a Chinese study in the American Journal of Clinical Nutrition found that women who were in the top fifth of fiber consumers were 11 percent less likely to develop breast cancer than those who were in the bottom fifth. Reuters notes that the findings do not prove that fiber lowers breast cancer risk. Fiber consumers may just be healthier overall. Also, Dr. Linos, from Stanford, noted that the potential effect of fiber was "very small." More on diet and breast cancer can be found on the fruits, vegetables and nuts page of the LATESTBreastCancer.com website.
Medical News Today reports that a Harvard study in the Journal of the National Cancer Institute discovered that women whose mammograms reveal dense breasts have not only a greater risk of breast cancer, but a greater risk of developing more aggressive tumors. The women in the study were postmenopausal. Higher breast density was associated with larger tumors, higher-grade tumors, estrogen receptor-negative status and a higher risk of developing ductal carcinoma in situ (DCIS). This was the first study to link breast density with tumor characteristics.
From the biology labs, BRCA 1/2 gene mutations have long been associated with a higher risk of breast cancer. Yesterday, a EurekAlert! press release discussed a Spanish study which examined the chromosomes of BRCA carriers. It found that BRCA 1/2 carriers have chromosomes with short telomeres, which are complex structures that protect the end of chromosomes. Interestingly, it also found "genetic anticipation" of breast cancer in daughters whose telomeres were shorter than their mother's. According to the press release, "The significance of generational changes in telomere length has interesting potential clinical applications in the management of familial breast cancer, and could be extended to other hereditary cancer syndromes."
Low risk of some serious side effects when Tamoxifen is taken for prevention
According to a July 18 study in Cancer Treatment Reviews, women younger than 50 who take tamoxifen for breast cancer prevention have only a low risk of developing endometrial cancer, deep vein thrombosis and pulmonary embolism. The risk decreases from the active to follow-up phase of treatment. The authors note that education and counseling are "the cornerstones of breast cancer chemoprevention."
Please check back on Monday for the weekend breast cancer news highlights. Even though we don't write the daily news blog on the weekends, we continue to add the latest breast cancer news and research to the LATESTBreastCancer.com website and database.
U.S. breast cancer incidence rates vary by estrogen receptor status
Yesterday, msnbc.com, citing a Journal of the National Cancer Institute study, revealed that although American breast cancer incidence rates appear to be stable, rates of estrogen-receptor negative breast cancer are actually falling and rates of estrogen-receptor positive breast cancer are on the rise. The decline in ER-negative breast cancer, which is more difficult to treat, is good news. The rise in ER-positive tumors, however, is concerning, and will likely be the focus of future research on risk and prevention.
Three new risk studies: fiber, breast density and BRCA biology
According to Reuters, a Chinese study in the American Journal of Clinical Nutrition found that women who were in the top fifth of fiber consumers were 11 percent less likely to develop breast cancer than those who were in the bottom fifth. Reuters notes that the findings do not prove that fiber lowers breast cancer risk. Fiber consumers may just be healthier overall. Also, Dr. Linos, from Stanford, noted that the potential effect of fiber was "very small." More on diet and breast cancer can be found on the fruits, vegetables and nuts page of the LATESTBreastCancer.com website.
Medical News Today reports that a Harvard study in the Journal of the National Cancer Institute discovered that women whose mammograms reveal dense breasts have not only a greater risk of breast cancer, but a greater risk of developing more aggressive tumors. The women in the study were postmenopausal. Higher breast density was associated with larger tumors, higher-grade tumors, estrogen receptor-negative status and a higher risk of developing ductal carcinoma in situ (DCIS). This was the first study to link breast density with tumor characteristics.
From the biology labs, BRCA 1/2 gene mutations have long been associated with a higher risk of breast cancer. Yesterday, a EurekAlert! press release discussed a Spanish study which examined the chromosomes of BRCA carriers. It found that BRCA 1/2 carriers have chromosomes with short telomeres, which are complex structures that protect the end of chromosomes. Interestingly, it also found "genetic anticipation" of breast cancer in daughters whose telomeres were shorter than their mother's. According to the press release, "The significance of generational changes in telomere length has interesting potential clinical applications in the management of familial breast cancer, and could be extended to other hereditary cancer syndromes."
Low risk of some serious side effects when Tamoxifen is taken for prevention
According to a July 18 study in Cancer Treatment Reviews, women younger than 50 who take tamoxifen for breast cancer prevention have only a low risk of developing endometrial cancer, deep vein thrombosis and pulmonary embolism. The risk decreases from the active to follow-up phase of treatment. The authors note that education and counseling are "the cornerstones of breast cancer chemoprevention."
Please check back on Monday for the weekend breast cancer news highlights. Even though we don't write the daily news blog on the weekends, we continue to add the latest breast cancer news and research to the LATESTBreastCancer.com website and database.
Wednesday, July 13, 2011
The Breast Cancer News Update: July 13
Today in breast cancer news, we'll highlight recent studies on molecular breast imaging and a study of molecular changes in tamoxifen resistant breast cancer recurrences.
Two Molecular Breast Imaging (MBI) studies
This week we added two studies on molecular breast imaging (MBI) to the LATESTBreastCancer.com website and database. MBI is also knowsn as breast-specific gamma imaging (BSGI).
Molecular breast imaging of invasive cancer
A June 28 study from George Washington University published in The British Journal of Radiology evaluated the sensitivity of BSGI in 139 women with invasive breast cancer. BSGI was found to have "a high sensitivity for the detection of invasive breast cancer." The authors concluded that BSGI "can reliably detect invasive breast cancers and is a useful adjunct imaging modality for the diagnosis of breast cancer."
Molecular breast imaging of DCIS
A July 8 study in the Annals of Surgical Oncology compared BSGI to MRI for the detection of DCIS. 18 patients recently diagnosed with DCIS were enrolled in the study. One tumor was not seen on either MRI or BSGI. One was seen on MRI only. In all, the sensitivity was 94% for MRI and 89% for BSGI. The authors concluded that "BSGI is equally as sensitive as MRI at detecting newly diagnosed DCIS." Future studies are needed due to the "limited number of patients enrolled" in this study.
Biomarker changes in tamoxifen resistant recurrent breast cancer
Sometimes even though a primary breast tumor was responsive to tamoxifen therapy, a recurrent tumor will be resistant to tamoxifen. A July 6 British study published in Endocrine-Related Cancer examined the molecular changes in tamoxifen resistant recurrent tumors to try to determine why. The study confirmed that some tamoxifen resistant tumors lose estrogen or progesterone receptor status and gain HER2 positive status. IGF1R gain, PTEN loss and PI3KCA mutations did not appear to contribute to tamoxifen resistance. This study confirms the importance of hormone receptor and HER2 status testing of recurrent breast cancer to determine the best course of treatment.
Please check back tomorrow for more breast cancer news and research highlights from LATESTBreastCancer.com.
Two Molecular Breast Imaging (MBI) studies
This week we added two studies on molecular breast imaging (MBI) to the LATESTBreastCancer.com website and database. MBI is also knowsn as breast-specific gamma imaging (BSGI).
Molecular breast imaging of invasive cancer
A June 28 study from George Washington University published in The British Journal of Radiology evaluated the sensitivity of BSGI in 139 women with invasive breast cancer. BSGI was found to have "a high sensitivity for the detection of invasive breast cancer." The authors concluded that BSGI "can reliably detect invasive breast cancers and is a useful adjunct imaging modality for the diagnosis of breast cancer."
Molecular breast imaging of DCIS
A July 8 study in the Annals of Surgical Oncology compared BSGI to MRI for the detection of DCIS. 18 patients recently diagnosed with DCIS were enrolled in the study. One tumor was not seen on either MRI or BSGI. One was seen on MRI only. In all, the sensitivity was 94% for MRI and 89% for BSGI. The authors concluded that "BSGI is equally as sensitive as MRI at detecting newly diagnosed DCIS." Future studies are needed due to the "limited number of patients enrolled" in this study.
Biomarker changes in tamoxifen resistant recurrent breast cancer
Sometimes even though a primary breast tumor was responsive to tamoxifen therapy, a recurrent tumor will be resistant to tamoxifen. A July 6 British study published in Endocrine-Related Cancer examined the molecular changes in tamoxifen resistant recurrent tumors to try to determine why. The study confirmed that some tamoxifen resistant tumors lose estrogen or progesterone receptor status and gain HER2 positive status. IGF1R gain, PTEN loss and PI3KCA mutations did not appear to contribute to tamoxifen resistance. This study confirms the importance of hormone receptor and HER2 status testing of recurrent breast cancer to determine the best course of treatment.
Please check back tomorrow for more breast cancer news and research highlights from LATESTBreastCancer.com.
Monday, May 23, 2011
The Breast Cancer News Update: May 23
All of today's breast cancer news involves early research. Although these discoveries are not yet available in clinical practice, it's interesting to see what's coming down the pike.
Link between obesity gene and breast cancer risk
Chicago researchers discovered a connection between obesity and breast cancer risk. In the study, people who possessed a variant in the fat mass and obesity associated gene (FTO) had a 30% greater risk of developing breast cancer. Everyone carries the FTO gene, but only 18% have the variant. Testing is not currently available.
Biomarker predicts Taxane-induced neuropathy
Researchers in Indiana identified a biomarker which predicts who is at risk for neuropathy, or nerve pain, numbness or tingling, from taxane chemotherapy, such as Taxol (paclitaxel). Again, a test is not currently available and further research is planned.
Protein is involved in development of tamoxifen resistance
UK researchers identified a protein which is involved in the development of tamoxifen resistance. In animal and cell studies, blocking the production of the protein made tamoxifen resistant cancer cells more responsive to tamoxifen. Scientists are now looking for drugs to block the effects of the protein.
At LATESTBreastCancer.com, we'll continue to follow these and other early breast cancer research developments. When something becomes clinically relevant, or an option for a patient today, even if off-label or in clinical trial, we add it to our database. All clinically relevant test and treatment options can be found on our website.
Link between obesity gene and breast cancer risk
Chicago researchers discovered a connection between obesity and breast cancer risk. In the study, people who possessed a variant in the fat mass and obesity associated gene (FTO) had a 30% greater risk of developing breast cancer. Everyone carries the FTO gene, but only 18% have the variant. Testing is not currently available.
Biomarker predicts Taxane-induced neuropathy
Researchers in Indiana identified a biomarker which predicts who is at risk for neuropathy, or nerve pain, numbness or tingling, from taxane chemotherapy, such as Taxol (paclitaxel). Again, a test is not currently available and further research is planned.
Protein is involved in development of tamoxifen resistance
UK researchers identified a protein which is involved in the development of tamoxifen resistance. In animal and cell studies, blocking the production of the protein made tamoxifen resistant cancer cells more responsive to tamoxifen. Scientists are now looking for drugs to block the effects of the protein.
At LATESTBreastCancer.com, we'll continue to follow these and other early breast cancer research developments. When something becomes clinically relevant, or an option for a patient today, even if off-label or in clinical trial, we add it to our database. All clinically relevant test and treatment options can be found on our website.
Wednesday, May 18, 2011
The Breast Cancer News Update: May 18
Here are today's top news stories.
First, there's breast cancer research news about a potential new biomarker to evaluate whether a patient will benefit from tamoxifen. According to a study in the Journal of Clinical Oncology this week, women whose tumors expressed active Stat5 were more likely to benefit from tamoxifen. Larger trials are planned to confirm the findings.
In insurance news, the Oregon Senate approved a bill to expand insurance coverage for breast reconstruction after breast cancer surgery. Although insurers are currently required to cover reconstruction after mastectomy, a loophole permitted them to deny coverage for breast conserving surgeries or lumpectomies. The bill heads next to the governor's desk.
Finally, we just added an Exercise Guide for Breast Cancer Survivors to the site. Thanks to our Twitter friends for sharing resources!
As always, at LATESTBreastCancer.com, we welcome all comments, feedback and news tips!
First, there's breast cancer research news about a potential new biomarker to evaluate whether a patient will benefit from tamoxifen. According to a study in the Journal of Clinical Oncology this week, women whose tumors expressed active Stat5 were more likely to benefit from tamoxifen. Larger trials are planned to confirm the findings.
In insurance news, the Oregon Senate approved a bill to expand insurance coverage for breast reconstruction after breast cancer surgery. Although insurers are currently required to cover reconstruction after mastectomy, a loophole permitted them to deny coverage for breast conserving surgeries or lumpectomies. The bill heads next to the governor's desk.
Finally, we just added an Exercise Guide for Breast Cancer Survivors to the site. Thanks to our Twitter friends for sharing resources!
As always, at LATESTBreastCancer.com, we welcome all comments, feedback and news tips!
Thursday, May 5, 2011
The Breast Cancer News Daily Update: May 6
It's Friday. Today we'll cover the morning breast cancer news and highlight the noteworthy abstracts from medical research publications we added to our database this week.
First the news.
This morning, The Telegraph (UK) reported that tamoxifen only reduces risk of breast cancer in about half of the women who take it for breast cancer prevention.
The screening mammography discussion continued today with a Reuters story about the impact of the US Preventative Services Task force recommendation against mammograms for women in their 40s on minority women. According to the report, "minority women are more likely to develop breast cancer in their forties than white women."
In prognostic testing, Irish and American researchers compared the OncotypeDX test to the PAM50 test. According to the story in Medical News Today, the tests predicted similar risk for those with high and low risk. For those with intermediate risk, the PAM50 identified more patients who would not benefit from chemotherapy.
Also in prognostic testing, French researchers reported that baseline circulating tumor cell (CTC) counts are prognostic at baseline for metastatic patients, and that CTC changes during treatment, "may be an early indicator of chemotherapy efficiency."
This week, we added a few interesting abstracts from breast cancer research medical publications to our database.
Researchers in Chicago reviewed hospital and emergency room admission records to see which 5-HT(3) RA class drugs for chemotherapy-related nausea and vomiting were most effective. They concluded that breast cancer patients on cyclophosphamide-based chemotherapy had "a significantly lower risk" of hospital-related nausea and vomiting if they started and continued taking palonosetron (brand name Aloxi).
The Annals of Plastic Surgery published a study that found "nearly 1 in 5" healthy breasts removed during a contralateral prophylactic mastectomy contained a malignant or pre-malignant lesion. Risk factors for finding a malignancy in a healthy breast included "a lobular histology in the original specimen" and patient age over 54.
In the UK, a study in The British Journal of Cancer found clinical benefit in continuing trastuzumab (brand name Herceptin) beyond disease progression in patients with locally advanced or metastatic HER2 positive disease.
Please check back Sunday evening for a recap of the weekend breast cancer news. As always, at LATESTBreastCancer.com we welcome any and all feedback. We want to know what interests you most.
First the news.
This morning, The Telegraph (UK) reported that tamoxifen only reduces risk of breast cancer in about half of the women who take it for breast cancer prevention.
The screening mammography discussion continued today with a Reuters story about the impact of the US Preventative Services Task force recommendation against mammograms for women in their 40s on minority women. According to the report, "minority women are more likely to develop breast cancer in their forties than white women."
In prognostic testing, Irish and American researchers compared the OncotypeDX test to the PAM50 test. According to the story in Medical News Today, the tests predicted similar risk for those with high and low risk. For those with intermediate risk, the PAM50 identified more patients who would not benefit from chemotherapy.
Also in prognostic testing, French researchers reported that baseline circulating tumor cell (CTC) counts are prognostic at baseline for metastatic patients, and that CTC changes during treatment, "may be an early indicator of chemotherapy efficiency."
This week, we added a few interesting abstracts from breast cancer research medical publications to our database.
Researchers in Chicago reviewed hospital and emergency room admission records to see which 5-HT(3) RA class drugs for chemotherapy-related nausea and vomiting were most effective. They concluded that breast cancer patients on cyclophosphamide-based chemotherapy had "a significantly lower risk" of hospital-related nausea and vomiting if they started and continued taking palonosetron (brand name Aloxi).
The Annals of Plastic Surgery published a study that found "nearly 1 in 5" healthy breasts removed during a contralateral prophylactic mastectomy contained a malignant or pre-malignant lesion. Risk factors for finding a malignancy in a healthy breast included "a lobular histology in the original specimen" and patient age over 54.
In the UK, a study in The British Journal of Cancer found clinical benefit in continuing trastuzumab (brand name Herceptin) beyond disease progression in patients with locally advanced or metastatic HER2 positive disease.
Please check back Sunday evening for a recap of the weekend breast cancer news. As always, at LATESTBreastCancer.com we welcome any and all feedback. We want to know what interests you most.
Subscribe to:
Posts (Atom)
